[1] 管文彩,张凌云,林群博,等.长链非编码RNA在肝癌化疗耐药中的研究进展.肝脏,2018,23:543-545.
[2] 刘凯,杜合娟,胡惠良,等.肝动脉化疗栓塞术对进展期肝癌淋巴转移者疗效及血管内皮生长因子表达的影响.中西医结合肝病杂志,2019,29:410-413.
[3] 李清华,崔龙久,刘双海,等.门静脉高压症对伴门静脉癌栓肝癌患者术后生存的影响.肝胆胰外科杂志,2019,31:335-340.
[4] 中国医师协会肝癌专业委员会.肝细胞癌合并门静脉癌栓多学科诊治中国专家共识(2018版).中华消化外科杂志,2019,18:8-15.
[5] 刘开才,吕维富,周春泽,等.TACE治疗原发性肝细胞癌合并门静脉癌栓疗效及影响因素.中国介入影像与治疗学,2018,15:331-336.
[6] Zhang X, Wang K, Wang M, et al. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. Oncotarget. 2017,8:29416-29427.
[7] Yu JI, Choi GS, Lim DH, et al. Treatment of Na?ve HCC combined with segmental or subsegmental portal vein tumor thrombosis: liver resection versus TACE followed by radiotherapy. Anticancer Res. 2018,38:4919-4925.
[8] 陈庆录,张冠平. TACE联合索拉非尼治疗肝癌合并门静脉癌栓的临床疗效及安全性.肝脏, 2019,24:573-576.
[9] 苏书娟,李红,张士腾,等.肝癌合并门静脉癌栓患者术后行肝动脉化疗栓塞序贯门静脉化疗栓塞的临床研究.中华肝胆外科杂志,2018,24:240-244.
[10] 王世材,于世平,李玲玲,等. TACE联合栓塞治疗中晚期肝癌合并肝动脉-门静脉瘘.中国介入影像与治疗学, 2019, 16:721-725.
[11] Wolter K, Decker G, Kuetting D, et al. Interventional Treatment of Acute Portal Vein Thrombosis. Rofo. 2018,190:740–746.
[12] 余天柱,罗剑钧,颜志平.血管内近程放疗与序贯三维适形放疗治疗门静脉主干癌栓的疗效对比.介入放射学杂志, 2017, 26:787-792.
[13] Yu Y, Zhong Y, Wang J, et al. Sarcomatoid hepatocellular carcinoma (SHC): a case report.World J Surg Oncol. 2017,15:219.
[14] 王飞.TACE联合CT引导下射频消融术治疗肝癌的疗效与安全性分析.现代医用影像学,2017,26:1453-1455.
[15] 朱楠,鲁东,肖景坤,等.肝动脉化疗栓塞联合射频消融术治疗中晚期肝癌的疗效.中国介入影像与治疗学,2017,14:195-199.
[16] Giorgio A, Merola MG, Montesarchio L, et al. Sorafenib combined with radio-frequency ablation compared with sorafenib alone in treatment of hepatocellular carcinoma invading portal vein: a western randomized controlled trial . Anticancer Res. 2016,36:6179-6183.
[17] Ozderya A, Aydin K, Gokkaya N, et al. Percutaneous ethanol injection for benign cystic and mixed thyroid nodules . Endocr Pract. 2018,24:548-555.
[18] Asilian A, Shahbazi M, Abtahi-Naeini B, Poostiyan N, Nilforoushzadeh MA. Percutaneous ethanol injection as a promising and minimally invasive treatment for axillary osmidrosis: double-blinded randomized controlled trial. Indian J Dermatol Venereol Leprol. 2018,84:157-162.
[19] 马顺茂,刘红磊,刘永红,等.肝动脉化疗栓塞联合无水酒精消融术治疗原发性肝癌的疗效及安全性分析.肝胆外科杂志, 2019,27:47-50.
[20] 刘邦.经皮穿刺无水酒精注射联合肝动脉栓塞术治疗原发性肝癌的效果观察.白求恩医学杂志,2019,17:107-108.
[21] 谢宝杰,朱丽娜,张凤娟,等.索拉非尼治疗原发性肝癌合并PVTT患者的临床治疗效果研究.基因组学与应用生物学, 2018,37:2685-2689.
[22] 林介军,卢立杰,金小军,等. 门脉内支架同步~(125)I粒子条植入序贯经肝动脉化疗栓塞治疗原发性肝癌合并门脉癌栓的效果.中国医药导报, 2018,15:85-88.
[23] 陈亚进,商昌珍,罗旋,等.复发性肝癌合并门静脉癌栓的多学科综合治疗.中华消化外科杂志,2017,16:430-432. |
